Skin pigment - absent or very little (albinism)
Also known as: Albinism
Methodology & AI Transparency ⓘ
Skin pigment - absent or very little (albinism) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (E70.30), workup for Skin pigment - absent or very little (albinism) (also termed Albinism) integrates contact/systemic trigger review [Skin pigment - absent or very little (albinism) E70.30] with evidence-graded therapy tailored to 25-Hydroxy Vitamin D in Skin pigment - absent or very little (albinism) (E70.30: & hs-CRP) response.
- 2 Real-world patient consensus: Synonyms for Skin pigment - absent or very little (albinism) (E70.30): Albinism (Skin & Dermatology).
- 3 Typical cash cost range: Clinicians assessing Skin pigment - absent or very little (albinism) focus on keratinocyte hyperproliferation [Skin pigment - absent or very little (albinism) E70.30] and targeted history.
- 4 Top reported side effects / signs: Key Skin & Dermatology biomarkers for Skin pigment - absent or very little (albinism) (E70.30): 25-Hydroxy Vitamin D in Skin pigment - absent or very little (albinism) (E70.30: & hs-CRP) & Affected Body Surface in Skin pigment - absent or very little (albinism) (E70.30: Area (BSA /) (Clear or Almost Clear (IGA 0–1) (E70.30)).
Ask our AI Specialists anything about Skin pigment - absent or very little (albinism)
What Is Skin pigment - absent or very little (albinism)?
Under Dermatology: Acne, Eczema, Psoriasis & Rosacea diagnostic criteria (E70.30), workup for Skin pigment - absent or very little (albinism) (also termed Albinism) integrates contact/systemic trigger review [Skin pigment - absent or very little (albinism) E70.30] with evidence-graded therapy tailored to 25-Hydroxy Vitamin D in Skin pigment - absent or very little (albinism) (E70.30: & hs-CRP) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Skin pigment - absent or very little (albinism) (E70.30) alters skin & dermatology homeostasis through keratinocyte hyperproliferation [Skin pigment - absent or very little (albinism) E70.30]; clinical remission targets Affected Body Surface in Skin pigment - absent or very little (albinism) (E70.30: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (E70.30).
Common Symptoms & Clinical Signs
- • Presentation of Skin pigment - absent or very little (albinism) (E70.30): persistent erythematous plaques, in Skin pigment - absent or very little (albinism) (E70.30: scaly patches, pruritic)
- • Secondary Skin pigment - absent or very little (albinism) clinical sign: compromised epidermal barrier in Skin pigment - absent or very little (albinism) (E70.30: with dryness, fissuring,)
- • Symptom flares in Skin pigment - absent or very little (albinism) correlating with 25-Hydroxy Vitamin D in Skin pigment - absent or very little (albinism) (E70.30: & hs-CRP) deviation outside 25(OH)D 40–65 ng/mL (E70.30)
- • Functional skin & dermatology impact requiring contact/systemic trigger review [Skin pigment - absent or very little (albinism) E70.30] evaluation (E70.30)
Skin pigment - absent or very little (albinism) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E70.30 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Skin pigment - absent or very little (albinism) (E70.30: & hs-CRP) | 25(OH)D 40–65 ng/mL (E70.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Skin pigment - absent or very little (albinism) (E70.30: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (E70.30) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Skin pigment - absent or very little (albinism) (E70.30: ALT (if systemic) | Within baseline reference limits (E70.30) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Skin pigment - absent or very little (albinism)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Curist Mucus Relief (Guaifenesin) Curist Mucus Relief • RxCUI 636522 | Expectorant | 94% | $0.0110 | $ 9.29 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Skin pigment - absent or very little (albinism))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients: What a 1,614-Participant Study Found Once-daily treatment with tazarotene 0.045% polymeric emulsion lotion may help improve patient-perceived skin oiliness in those with moderate-to-severe acne. The Journal of dermatological treatment • 2023-12-15 • Randomized Controlled Trial | N = 1,614 | 96/100 | PMID 36382987 ↗ |
| New Insights on Accuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy: What a 1,564-Participant Study Found The diagnostic performance of the EC skin test was similar to that of the T-SPOT test in the healthy population and was unaffected by BCG vaccination. BMC infectious diseases • 2024-12-30 • Phase III Randomized Trial | N = 1,564 | 96/100 | PMID 39736611 ↗ |
| New Insights on Incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic: What a 259-Participant Study Found The incidence of TD was relatively low in both younger and older patients with depression with psychotic features treated acutely with olanzapine. Journal of clinical psychopharmacology • 2013-06-15 • Randomized Controlled Trial | N = 259 | 93/100 | PMID 23609383 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| New Insights on Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years: What a 304-Participant Study Found Treatment with dupilumab provides significant and sustained improvements within 2 weeks in AD signs, symptoms, and QoL in almost all children with severe AD, including those who did not achieve clear or almost clear skin by... American journal of clinical dermatology • 2023-09-15 • Phase III Randomized Trial | N = 304 | 93/100 | PMID 37300760 ↗ |
Skin pigment - absent or very little (albinism) Patient Community & “People Like Me” Threads
Filter Skin pigment - absent or very little (albinism) community threads and patient logs by age, biological sex, dosage, and treatment duration.